Skip to main content
FinSpry Logo
FinSpry
AKTS logo
AKTS
(NASDAQ)
Aktis Oncology, Inc.
$24.06-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Aktis Oncology, Inc. (AKTS) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Aktis Oncology, Inc. stock.

Analyst Consensus Rating

Investment consensus from 3 professional research analysts

Consensus Rating

Buy
Based on 3 unique analysts
Low Confidence∞:1 Buy/Sell

Average Price Target

$36.67
↑ 52.41% Upside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest AKTS Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

David Lebowitz
BMO Capital
BuyInitiates
$37.00
Jessica Fye
JP Morgan
BuyReiterates
$30.00 → $33.00
Christopher Raymond
Raymond James
BuyInitiates
$40.00

Frequently Asked Questions

What is the analyst consensus rating for AKTS?

The analyst consensus rating for AKTS is "Buy" based on 3 analyst recommendations.

What is the average price target for AKTS?

The average 12-month price target for AKTS is $36.67, representing an upside of 52.4% from the current price of $24.06.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.